2025
SJR Q1
JCR Q1 · 4,5
12 matched articles
SCIE
Journal detail
Expert Opinion on Drug Metabolism and Toxicology
- Publisher
- Taylor and Francis Ltd.
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
1742525517447607
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,986
- Quartile Q1
- H-Index 112
- Cites/doc 4,52
- Docs (3y) 231
- Cites (3y) 1.017
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 4,5
- 5Y JIF 4,7
- JCI 0,53
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Medicine (miscellaneous) Q1
- Pharmacology Q2
- Toxicology Q1
Areas
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS categories
- Biochemistry & Molecular Biology | Pharmacology & Pharmacy | Toxicology
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 0,986 | 4,5 | 4,7 | 0,53 | Q3 | 112 |
| 2024 | Q1 | Q2 | 0,986 | 3,4 | 4,3 | 0,53 | Q3 | 104 |
| 2023 | Q1 | Q1 | 0,987 | 3,9 | 4,3 | 0,55 | Q3 | 104 |
| 2022 | Q1 | Q1 | 0,895 | 4,3 | 4,2 | 0,59 | Q3 | 104 |
| 2021 | Q1 | Q1 | 0,92 | 4,9 | 4,4 | 0,64 | Q3 | 104 |
| 2020 | Q1 | Q1 | 1,031 | 4,5 | 4,1 | 0,7 | Q2 | 104 |
| 2019 | Q1 | Q2 | 0,93 | 3,5 | 3,2 | 0,65 | Q3 | 104 |
| 2018 | — | Q2 | — | 3,5 | 3,1 | 0,56 | Q3 | — |
| 2017 | Q1 | Q2 | 0,954 | 3,2 | 3 | 0,51 | Q3 | 104 |
| 2016 | Q1 | Q2 | 0,928 | 3 | 2,8 | — | — | 104 |
| 2015 | Q2 | Q2 | 0,865 | 2,6 | 2,5 | — | — | 104 |
| 2014 | Q1 | Q2 | 0,906 | 2,8 | 2,7 | — | — | 104 |
| 2013 | Q1 | Q2 | 0,906 | 2,9 | 3,1 | — | — | 104 |
| 2012 | Q1 | Q2 | 0,942 | 2,9 | 3,2 | — | — | 104 |
| 2011 | Q1 | Q2 | 1,018 | 3,1 | 3,4 | — | — | 104 |
| 2010 | Q1 | Q2 | 1,043 | 3,4 | — | — | — | 104 |
| 2009 | — | Q2 | — | 3,1 | — | — | — | — |
| 2008 | — | Q2 | — | 3,1 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | Q3 | 103/328 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 90/356 |
| 2025 | TOXICOLOGY | SCIE | Q1 | Q3 | 26/106 |
| 2024 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | Q3 | 138/320 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 113/352 |
| 2024 | TOXICOLOGY | SCIE | Q2 | Q3 | 34/106 |
| 2023 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | Q3 | 106/313 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q3 | 85/354 |
| 2023 | TOXICOLOGY | SCIE | Q1 | Q3 | 23/106 |
| 2022 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | Q3 | 108/285 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 87/278 |
| 2022 | TOXICOLOGY | SCIE | Q1 | Q3 | 20/94 |
| 2021 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | Q3 | 113/297 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 82/279 |
| 2021 | TOXICOLOGY | SCIE | Q1 | Q3 | 21/94 |
| 2020 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | Q3 | 111/295 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 84/276 |
| 2020 | TOXICOLOGY | SCIE | Q1 | Q3 | 22/93 |
| 2019 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | Q3 | 124/297 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 84/271 |
| 2019 | TOXICOLOGY | SCIE | Q2 | Q3 | 24/92 |
| 2018 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | Q3 | 117/299 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 74/267 |
| 2018 | TOXICOLOGY | SCIE | Q2 | Q4 | 27/93 |
| 2017 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | Q3 | 126/293 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q3 | 83/261 |
| 2017 | TOXICOLOGY | SCIE | Q2 | Q4 | 31/94 |
| 2016 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 133/290 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 86/257 |
| 2015 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q3 | — | 150/289 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 101/255 |
| 2014 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 138/290 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 94/255 |
| 2013 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 137/291 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 82/256 |
| 2012 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 131/290 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 79/261 |
| 2011 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 121/290 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 73/261 |
| 2010 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 112/286 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 66/252 |
| 2009 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 112/283 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 71/237 |
| 2008 | BIOCHEMISTRY & MOLECULAR BIOLOGY | SCIE | Q2 | — | 112/275 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 65/219 |